A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of e...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Jin, Yangbing, Zhang, Zehui, Zou, Siyi, Li, Fanlu, Chen, Hao, Peng, Chenghong, Deng, Xiaxing, Wen, Chenlei, Shen, Baiyong, Zhan, Qian
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2021
נושאים:
Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010262/
https://ncbi.nlm.nih.gov/pubmed/33816276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.634881
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים